Business Wire

C3.ai Announces COVID-19 Grand Challenge Winners

8.12.2020 17:00:00 EET | Business Wire | Press release

Share

C3.ai, a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today announced the winners of the C3.ai™ COVID-19 Grand Challenge. Launched on Sept. 15, the global competition encouraged developers, data scientists, students, and creative minds to build world-class data science techniques and strategies that accelerate novel COVID-19 research and drive smart and safe decision-making. The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic.

After a rigorous review process, the judging panel selected seven research projects for recognition. Judges assessed how well the entries leveraged data science techniques to derive insights that were not apparent before. The judges selected submissions that were most likely to unlock significant public health and economic benefits.

A total of $200,000 in cash prizes will be awarded to these research teams. Each has developed meaningful data-driven insights that will help the global community understand and mitigate not only the spread of COVID-19, but also prepare the world to fight future pandemics, improve the medical community’s ability to respond, and help policymakers navigate decisions about COVID-19.

C3.ai Grand Challenge Award Winners:

Grand Prize - $100,000

  • Combined Diagnostics - Modeling Population Heterogeneity and Personalized COVID Diagnostics. Predicts an individual’s infectious and susceptibility status and probability of having COVID-19. The team applied the Bayesian Stochastic Expectation-Maximization method to demographics, individual health characteristics, and behavioral and geographical data to provide personalized estimates for each individual’s infectious and susceptibility statuses. (Freddy Bunbury - Carnegie Institution for Science, Nina Miolane - University of California, Santa Barbara, and Claire Donnat - University of Chicago)

“Any return to normality relies on accurately determining who might have COVID-19. Demographics, individual health characteristics, and behavioral and geographical data considerably alter one’s risk of catching, suffering from, and spreading the virus,” said Freddy Bunbury, post-doctoral researcher at the Carnegie Institution for Science. “Knowing this, we developed a machine learning model that is reactive, granular, and even personalized to help individuals, and – by extension – society, compute with greater accuracy the probability of having COVID-19. By intelligently combining these disparate data sources, we aim to more robustly capture people’s individual likelihood of having and spreading the disease, reduce false test results, and inform disease transmission models.”

“This project has huge potential to make an immediate impact on the pandemic with its approach to generating meaningful results from COVID testing,” said Thomas M. Siebel, CEO of C3.ai. “This is an unprecedented opportunity to apply informed decision-making based on data to enable daily life and business operations to continue, while effectively managing health risks.”

Second-Place Awards - $25,000 each

  • DeepOutbreak: Framework for Forecasting Dynamics of COVID-19 and Co-Evolving Diseases. Models the progression of COVID-19 and symptomatically similar co-evolving influenza-like illnesses, as well as hospitalization and mortality rates. Designed to optimize healthcare deployment, which is especially important with hospitalizations resurging and healthcare workers increasingly becoming ill. (Alexander Rodriguez, Nikhil Muralidhar, Bijaya Adhikari, Naren Ramakrishnan, and B. Aditya Prakash - U.S.)
  • Assessing Conservation Level of Therapeutic and Vaccine Targets of COVID-19. Predicts the effectiveness of vaccines and therapeutics by genome sequences and prioritizes relevant treatments to inform drug and vaccine development. (Yuanfang Guan and Manqi Zhou - U.S.)

Third-Place Awards - $12,500 each

  • Analysis of COVID-19 Policies’ Impact on the Population and the Economy . Calculates the impact of government policies on COVID-19 infection rates, stock prices, and a population’s mobility to inform governments about how policies affect people and the economy. (Niti Wattanasirichaigoon, Napat Ratanakul, and Apiwat Jaroonpol - U.S., Singapore, and Japan)
  • COVIDProf: An Intelligent Q&A Chatbot Tuned to Deliver Scientific Research and Data Related to COVID-19 in Natural Language. Makes finding and understanding relevant COVID-19 scientific research and data easier for the average person through an intelligent Q&A chatbot. (Varsha Rao and Joy Yeh - Singapore and Japan)
  • Structural Modeling of COVID Spread in Relation to Human Mobility . Models causal relationships between human mobility indicators (trips, distance traveled, staying at home, and social distancing) and COVID-19 spread to inform how policymakers should take action. (Rezwana Rafiq, Tanjeeb Ahmed, and Md Yusuf Sarwar Uddin - U.S.)
  • The Center on Stochastic Modeling, Optimization, and Statistics (COSMOS) COVID -19 Linear Programming. Online tool for reopening communities that enables decision makers to study hypothetical scenarios to inform planning and protect high-risk individuals. (Victoria Chen, Yuan Zhou, Nilabh Ohol, Alireza Fallahi, and Amith Viswanatha - U.S.)

Award Criteria

The projects were reviewed on the basis of their scientific merit, the use of AI, machine learning, and/or other data science techniques in the project, and the incorporation of at least two data sources from the C3 AI® COVID-19 Data Lake.

The evaluation process also considered the extent to which the derived data science insights, if implemented at scale, will result in significant public health and economic benefit.

To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/c3-ai-covid-19-grand-challenge/.

About C3.ai

C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a proprietary, model-driven AI architecture that dramatically enhances data science and application development.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Kennedy
415-914-8336
pr@c3.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye